These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
236 related articles for article (PubMed ID: 21142652)
1. Increasing the antitumor efficacy of doxorubicin-loaded liposomes with peptides anchored via a chelator lipid. Herringson TP; Altin JG J Drug Target; 2011 Sep; 19(8):681-9. PubMed ID: 21142652 [TBL] [Abstract][Full Text] [Related]
2. Effective tumor targeting and enhanced anti-tumor effect of liposomes engrafted with peptides specific for tumor lymphatics and vasculature. Herringson TP; Altin JG Int J Pharm; 2011 Jun; 411(1-2):206-14. PubMed ID: 21443937 [TBL] [Abstract][Full Text] [Related]
3. The novel chelator lipid 3(nitrilotriacetic acid)-ditetradecylamine (NTA(3)-DTDA) promotes stable binding of His-tagged proteins to liposomal membranes: potent anti-tumor responses induced by simultaneously targeting antigen, cytokine and costimulatory signals to T cells. van Broekhoven CL; Altin JG Biochim Biophys Acta; 2005 Oct; 1716(2):104-16. PubMed ID: 16225839 [TBL] [Abstract][Full Text] [Related]
4. Improved tumor-targeting drug delivery and therapeutic efficacy by cationic liposome modified with truncated bFGF peptide. Chen X; Wang X; Wang Y; Yang L; Hu J; Xiao W; Fu A; Cai L; Li X; Ye X; Liu Y; Wu W; Shao X; Mao Y; Wei Y; Chen L J Control Release; 2010 Jul; 145(1):17-25. PubMed ID: 20307599 [TBL] [Abstract][Full Text] [Related]
5. Experimental anticancer therapy with vascular-disruptive peptide and liposome-entrapped chemotherapeutic agent. Sochanik A; Mitrus I; Smolarczyk R; Cichoń T; Snietura M; Czaja M; Szala S Arch Immunol Ther Exp (Warsz); 2010 Jun; 58(3):235-45. PubMed ID: 20383751 [TBL] [Abstract][Full Text] [Related]
6. Combined targeting of perivascular and endothelial tumor cells enhances anti-tumor efficacy of liposomal chemotherapy in neuroblastoma. Loi M; Marchiò S; Becherini P; Di Paolo D; Soster M; Curnis F; Brignole C; Pagnan G; Perri P; Caffa I; Longhi R; Nico B; Bussolino F; Gambini C; Ribatti D; Cilli M; Arap W; Pasqualini R; Allen TM; Corti A; Ponzoni M; Pastorino F J Control Release; 2010 Jul; 145(1):66-73. PubMed ID: 20346382 [TBL] [Abstract][Full Text] [Related]
7. Convenient targeting of stealth siRNA-lipoplexes to cells with chelator lipid-anchored molecules. Herringson TP; Altin JG J Control Release; 2009 Nov; 139(3):229-38. PubMed ID: 19595724 [TBL] [Abstract][Full Text] [Related]
8. Polyethylene glycol-complexed cationic liposome for enhanced cellular uptake and anticancer activity. Jung SH; Jung SH; Seong H; Cho SH; Jeong KS; Shin BC Int J Pharm; 2009 Dec; 382(1-2):254-61. PubMed ID: 19666094 [TBL] [Abstract][Full Text] [Related]
9. Lactoferrin modified doxorubicin-loaded procationic liposomes for the treatment of gliomas. Chen H; Qin Y; Zhang Q; Jiang W; Tang L; Liu J; He Q Eur J Pharm Sci; 2011 Sep; 44(1-2):164-73. PubMed ID: 21782939 [TBL] [Abstract][Full Text] [Related]
10. Vascular targeting of doxorubicin using cationic liposomes. Wu J; Lee A; Lu Y; Lee RJ Int J Pharm; 2007 Jun; 337(1-2):329-35. PubMed ID: 17275230 [TBL] [Abstract][Full Text] [Related]
11. Targeting of plasmid DNA-lipoplexes to cells with molecules anchored via a metal chelator lipid. Herringson TP; Patlolla RR; Altin JG J Gene Med; 2009 Nov; 11(11):1048-63. PubMed ID: 19757485 [TBL] [Abstract][Full Text] [Related]
12. Anti-CD19-targeted liposomal doxorubicin improves the therapeutic efficacy in murine B-cell lymphoma and ameliorates the toxicity of liposomes with varying drug release rates. Allen TM; Mumbengegwi DR; Charrois GJ Clin Cancer Res; 2005 May; 11(9):3567-73. PubMed ID: 15867261 [TBL] [Abstract][Full Text] [Related]
13. Targeting dendritic cells with antigen-containing liposomes: a highly effective procedure for induction of antitumor immunity and for tumor immunotherapy. van Broekhoven CL; Parish CR; Demangel C; Britton WJ; Altin JG Cancer Res; 2004 Jun; 64(12):4357-65. PubMed ID: 15205352 [TBL] [Abstract][Full Text] [Related]
14. Ultrasound enhanced antitumor activity of liposomal doxorubicin in mice. Hagtvet E; Evjen TJ; Olsen DR; Fossheim SL; Nilssen EA J Drug Target; 2011 Sep; 19(8):701-8. PubMed ID: 21524240 [TBL] [Abstract][Full Text] [Related]
15. A novel peptide probe for imaging and targeted delivery of liposomal doxorubicin to lung tumor. He X; Na MH; Kim JS; Lee GY; Park JY; Hoffman AS; Nam JO; Han SE; Sim GY; Oh YK; Kim IS; Lee BH Mol Pharm; 2011 Apr; 8(2):430-8. PubMed ID: 21222482 [TBL] [Abstract][Full Text] [Related]
17. Targeted delivery of RGD-modified liposomes encapsulating both combretastatin A-4 and doxorubicin for tumor therapy: in vitro and in vivo studies. Zhang YF; Wang JC; Bian DY; Zhang X; Zhang Q Eur J Pharm Biopharm; 2010 Mar; 74(3):467-73. PubMed ID: 20064608 [TBL] [Abstract][Full Text] [Related]
18. Deoxycholic acid modified-carboxymethyl curdlan conjugate as a novel carrier of epirubicin: in vitro and in vivo studies. Gao F; Li L; Zhang H; Yang W; Chen H; Zhou J; Zhou Z; Wang Y; Cai Y; Li X; Liu L; Zhang Q Int J Pharm; 2010 Jun; 392(1-2):254-60. PubMed ID: 20347028 [TBL] [Abstract][Full Text] [Related]
19. Chloride channel-mediated brain glioma targeting of chlorotoxin-modified doxorubicine-loaded liposomes. Xiang Y; Liang L; Wang X; Wang J; Zhang X; Zhang Q J Control Release; 2011 Jun; 152(3):402-10. PubMed ID: 21435361 [TBL] [Abstract][Full Text] [Related]
20. Development of a novel cyclic RGD peptide for multiple targeting approaches of liposomes to tumor region. Amin M; Mansourian M; Koning GA; Badiee A; Jaafari MR; Ten Hagen TLM J Control Release; 2015 Dec; 220(Pt A):308-315. PubMed ID: 26526970 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]